idecabtagene vicleucel
bms,2seventy bio
congress #ims2022 | , presents data from the phase ii karmma study showing that patients who achieve early and sustained undetectable mrd after treatment with ide-cel have prolonged pfs. #medcongress #mmsm #cartcell #celltherapy 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma